RBC Capital analyst Leonid Timashev raised the firm’s price target on Axsome Therapeutics to $128 from $123 and keeps an Outperform rating on the shares. The analyst cites the company’s topline data from its phase 3 SYMPHONY trial of AXS-12 in cataplexy, with the drug showing a clear statistically significant hit on the primary endpoint, along with positive improvements in sleepiness, mood, and cognition and a clean safety profile. The readout has been less of a focus for investors, but the data clears the bar for a regulatory approval, while key opinion leader interest suggests that there should be at least a $350M commercial opportunity for the drug, RBC tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AXSM:
- Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients
- Axsome Therapeutics announces results of CRESCENDO narcolepsy survy
- Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in Narcolepsy
- Axsome Therapeutics says AXS-12 achieves primary endpoint in SYMPHONY trial
- Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive Disorder